Sandoz: Big Cap Biosimilar Rivals Lack Clarity On Commitment
Comments Follow Plans For Novartis To Spin Sandoz
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.
You may also be interested in...
Victory Swings Back To Gilenya Generics With Latest US Supreme Court Order
Novartis, which reportedly generates $3.8m per day in US Gilenya sales, is once again facing up to the prospect of imminent generic competition to its blockbuster treatment for relapsing-remitting multiple sclerosis, following the latest order by the US Supreme Court.
Sandoz Delivers Denosumab Data As Biogen Sues On Tysabri
Having previously identified itself as the frontrunner in the race to launch a biosimilar to Amgen’s Prolia, Sandoz has now delivered positive confirmatory data, shortly after being sued in the US over its Polpharma-partnered proposed Tysabri biosimilar.
EMA And HMA Speak Out In Favor Of Biosimilar Interchangeability
Stakeholders in Europe have been hesitant to allow interchangeable substitution of biological products, prompting the European Medicines Agency to clarify its stance on the issue.